All News

RheumNow Podcast square

Best Rheumatologists (7.19.2024)

Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
RheumNow Podcast square

Pollution and Autoimmunity (7.12.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
guidelines.recommendations.jpg

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

Jack Cush, MD

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article
hidradenitis.jpg

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Jack Cush, MD

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.

Read Article
heel enthesitis spur calcaneal

ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

Jack Cush, MD

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

Read Article
2001-2004 NHANES population study shows 28% report hx of erectile dysfunction (ED) & 19% w/ arthritis. Having arthritis was assoc w/ 4 fold higher ED risk; mostly in #OA (OR=1.11), RA (OR=1.03). https://t.co/L2LhEPH9DY https://t.co/yLhVmLw7nt

Links:

Dr. John Cush RheumNow ( View Tweet)
Best Rheumatologists (7.19.2024) Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern. https://t.co/2Tkdat6CXv https://t.co/1lOfbgNZvn

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective cohort study from 474 055 participants in UK Biobank, finds long-term exposure to air pollutants, NO2 etc, assoc w/ a 19% to 47% increased risk incident psoriasis. Air pollution and genetic predisposition also significantly incr incident PsO https://t.co/ogX81ybU3l https://t.co/Mvd6tAj2j6

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitor Brodalumab is not often talked about, but its approved for PsO & PsA. German study of 227 PsO w/ 37 PsA pts Rx w/ BRO - good, rapid response by 3 mos. 1 year drug survival rate was 76.2%, (mean discontinuation=8.3 mos. https://t.co/4byFoc96Zs https://t.co/sPomX0s8aa

Links:

Dr. John Cush RheumNow ( View Tweet)
Later onset PsO may benefit from earlier PsA screening. Cohort study of 384 Psoriasis pts. Older PsO onset assoc w/ shorter interval from PsO to PsA. PsO onset at 42.6 yrs had a 62% shorter interval & OR 4.56 to have PsA w/in 6 mos. https://t.co/DSiYs88MFa https://t.co/reID2wvLiu

Links:

Dr. John Cush RheumNow ( View Tweet)
In the US CorEvitas registry of 1823 PsA pts; 11.1% fulfilled fibromyalgia definition & 20.6% had widespread pain. FM was assoc w/ female, depression/anxiety, impaired function, increased BMI, comorbidities. cDAPSA, patient pain& TJC https://t.co/YwRBYo1aR6 https://t.co/TXraU0F3Mh

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Topic Panel: EULAR 2024 Dr. Jack Cush moderates this topic panel with Drs. Eric Ruderman, Peter Nash and Antoni Chan. https://t.co/XUFgUUqBu2 https://t.co/08TPtQWBvx

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations https://t.co/abcs8RwJ5J https://t.co/wLOq4bK7qQ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA) https://t.co/JjhkQM672t. https://t.co/dM25kIcC26

Links:

Dr. John Cush RheumNow ( View Tweet)
Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J

Links:

Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G

Links:

Dr. John Cush RheumNow ( View Tweet)
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/y3UvOF4M5i https://t.co/iSUrkhIXbh

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. https://t.co/BHnTciKU1f https://t.co/P7gDZUSGRw

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult-to-Treat Psoriasis This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics. https://t.co/OWzmYShqBs https://t.co/u1995MAB15

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×